Frailty and Potential Biomarkers in AgingJessica L. Lee1 and Yong Li2*
- *Corresponding Author:
- Yong Li
Center for Stem Cell and Regenerative Medicine
Brown Foundation Institute of Molecular
Medicine for the Prevention of Human Diseases, USA
E-mail: [email protected]
Received date: July 20, 2016; Accepted date: July 22, 2016; Published date: July 29, 2016
Citation: Lee JL, Li Y (2016) Frailty and Potential Biomarkers in Aging. J Aging Sci 4:e121. doi:10.4172/2329-8847.1000e121
Copyright: © 2016 Li Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Frailty is an age-related syndrome that has been well-described in the last ten years. It can be characterized by diminished strength, endurance, and reduced physiologic function. With multiple causes and contributors, frailty is highly correlated with functional decline and chronic diseases. Currently, there are no standardized tests or biomarkers that can be used to identify frail patients, though there have been a number of assessments used in research such as the Fried Frailty Phenotype or the Rockwood Frailty Index. Identification of biomarkers for frailty is a major consideration for future studies of this syndrome.